Why Travere Therapeutics Inc (TVTX) Stock Is Rising
As of 2026-11-12, Travere Therapeutics Inc (TVTX) has a next-year EPS growth estimate of 478.50%. Featured in 2 EPS revision reports, most recently on 2026-04-15.
Why TVTX Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Travere Therapeutics Inc's next-year EPS growth estimate from 457.46% to 478.50% on 2026-11-06.
- ·Current-Year Growth: Projected at -173.46%, supporting the forward estimate revision.
News Context
TVTX has been rising primarily because analysts raised the next-year EPS growth estimate to 478.50% from 457.46% on 2026-11
Generated 2026-11-11 · news as of 2026-11-10
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 478.50%
- EPS growth this year
- -173.46%
- EPS next quarter (est)
- $0.44
- Last price
- $51.56
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 478.50% | -173.46% | $0.44 | $51.56 |
| 2026-11-11 | 478.50% | -173.46% | $0.44 | $52.04 |
| 2026-11-10 | 478.50% | -173.46% | $0.44 | $51.99 |
| 2026-11-09 | 478.50% | -173.46% | $0.44 | $51.63 |
| 2026-11-07 | 478.50% | -173.46% | $0.44 | $49.60 |
| 2026-11-06 | 478.50% | -173.46% | $0.44 | $49.60 |
| 2026-11-05 | 457.46% | -180.06% | $0.39 | $48.87 |
| 2026-11-04 | 457.46% | -180.06% | $0.39 | $52.42 |
| 2026-11-03 | 619.50% | -110.55% | $0.45 | $49.41 |
| 2026-11-02 | 1318.39% | 19.03% | $0.45 | $49.26 |
| 2026-10-31 | 1318.39% | 19.03% | -$0.10 | $50.39 |
| 2026-10-30 | 1318.39% | 19.03% | -$0.10 | $50.39 |
| 2026-10-29 | 1318.39% | 19.03% | -$0.10 | $50.57 |
| 2026-10-28 | 1318.39% | 19.03% | -$0.10 | $50.85 |
| 2026-10-27 | 3706.44% | 70.47% | -$0.04 | $50.88 |
| 2026-10-26 | 3706.44% | 70.47% | -$0.04 | $49.97 |
| 2026-10-23 | 3571.33% | 69.32% | -$0.04 | $50.08 |
| 2026-10-22 | 3571.33% | 69.32% | -$0.04 | $52.43 |
| 2026-10-21 | 3571.33% | 69.32% | -$0.04 | $52.58 |
| 2026-10-20 | 2065.43% | 45.76% | -$0.07 | $52.30 |
| 2026-10-19 | 2065.43% | 45.76% | -$0.07 | $50.49 |
| 2026-10-16 | 10421.23% | 89.44% | $0.03 | $49.60 |
| 2026-10-15 | 10421.23% | 89.44% | $0.03 | $52.79 |
| 2026-10-14 | 10421.23% | 89.44% | $0.03 | $53.27 |
| 2026-10-13 | 10421.23% | 89.44% | $0.03 | $51.80 |
| 2026-10-12 | 10421.23% | 89.44% | $0.03 | $52.02 |
| 2026-10-11 | 10421.23% | 89.44% | $0.03 | $52.12 |
| 2026-10-10 | 10421.23% | 89.44% | $0.03 | $52.12 |
| 2026-10-09 | 10421.23% | 89.44% | $0.03 | $52.12 |
| 2026-10-08 | 10421.23% | 89.44% | $0.03 | $52.04 |
Reports Featuring TVTX
Recent News
- Travere Therapeutics to Report Third Quarter 2026 Financial ResultsBusiness Wire
- Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI (sparsentan) May Modify Underlying Disease Pathophysiology in IgA NephropathyBusiness Wire
- Travere Therapeutics Outlook Brightens As Turnaround LoomsInvestor's Business Daily
- Travere Therapeutics to Participate at Upcoming Investor ConferencesBusiness Wire
- Travere Therapeutics to Participate at Upcoming Investor ConferencesBusiness Wire
- Travere Therapeutics Inc (TVTX) (Q2 2026) Earnings Call Highlights: Record FILSPARI Demand and ...GuruFocus.com
- Four Biotech Stocks Near Buy Points As Earnings Season Kicks InInvestor's Business Daily
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Travere Therapeutics Inc (TVTX) stock go up recently?▾
Travere Therapeutics Inc (TVTX) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 457.46% to 478.50% on 2026-11-06. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Travere Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-11-12, Travere Therapeutics Inc (TVTX) has a next-year EPS growth estimate of 478.50%, based on analyst consensus.
When was the latest EPS estimate revision for TVTX?▾
The most recent revision occurred on 2026-11-06, when analysts adjusted the next-year EPS growth estimate from 457.46% to 478.50%.
What sector and industry does Travere Therapeutics Inc belong to?▾
Travere Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. TVTX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Travere Therapeutics Inc (TVTX) appears here because it was detected by our daily top-EPS-revision-performer screen.